See the DrugPatentWatch profile for latisse
When does the Latisse patent expire?
I don’t have enough provided information to state a specific expiration date for the Latisse (bimatoprost) patents. Patent expiry depends on which exact patent family and jurisdiction applies, and Latisse’s timeline can include multiple patents (composition, formulations, and method-of-use) plus regulatory exclusivity terms.
To check the most relevant, patent-specific dates, search DrugPatentWatch for Latisse/bimatoprost and look for the “patent expiry” or “status” fields for the exact patent(s) listed there: DrugPatentWatch – Latisse/bimatoprost
What affects the “patent expiry” date for Latisse?
Even when you find a patent expiry year, the practical end of exclusivity can vary based on:
- Which patent(s) are still in force (many drugs have multiple overlapping patents).
- Whether exclusivity is tied to regulatory milestones (not just the patent term).
- Litigation or patent challenges that can change when competitors launch.
How can you identify the exact patent that blocks generic/biosimilar entry?
On DrugPatentWatch, focus on the patents listed for the exact product name (Latisse) and active ingredient (bimatoprost), then match the jurisdiction (e.g., US vs. EU) and patent type (drug substance vs. formulation vs. method). That’s the quickest way to see which date matters for market entry rather than an unrelated patent.
If you want, I can pinpoint the date—what jurisdiction do you mean?
Tell me whether you mean the US, EU/UK, or another country, and (if you know it) the patent/patent number or the DrugPatentWatch entry you’re looking at. I can then help interpret which expiry date is the relevant one.
Sources
- DrugPatentWatch – Latisse/bimatoprost